CA2404226A1 — Furoisoquinoline derivatives, process for producing the same and use thereof
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2001-09-27 · 25y expired
What this patent protects
Compounds having the partial structure represented by the following formula (A) or salts thereof which have an excellent phosphodiesterase (PDE) IV inhibitory effect and are useful as preventives and remedies for diseases caused by inflammation, for example, bronchial asthma, chr…
USPTO Abstract
Compounds having the partial structure represented by the following formula (A) or salts thereof which have an excellent phosphodiesterase (PDE) IV inhibitory effect and are useful as preventives and remedies for diseases caused by inflammation, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, autoimmune disease and diabetes.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.